Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: a net income increase, but decreased cash reserves. Positive updates include regulatory approvals and promising drug trials. However, management's vague responses in the Q&A, particularly on PFS analysis and third-party milestones, raise concerns. The absence of guidance changes and reliance on future milestones temper optimism. Consequently, the stock reaction is predicted to be neutral.
Key Financial Performance
Total Revenue $27.6 million in the third quarter of 2025 compared to $16 million for the third quarter of 2024, representing a significant increase. The increase was primarily due to a $25 million nonrefundable milestone recognized from J&J in relation to clinical progress on pasritamig in Phase III studies in metastatic castration-resistant prostate cancer and $1 million of royalty revenues from Jazz and BeOne medicines. These increases were partially offset by a reduction in development support and drug supply revenue from Jazz and due to a nonrecurring milestone from GSK that was achieved in the third quarter of 2024.
Operating Expenses $49.7 million for the 3 months ended September 30, 2025, compared to $50.2 million for the same period in 2024, representing a decrease of 1%. The decrease was primarily due to a reduction in expenses from ZW220 and ZW251, zanidatamab and zanidatamab zovodotin and a decrease in personnel expenses. This was partially offset by an increase in preclinical and research expenses for our ZW209 and ZW1528 programs, progression of clinical studies for ZW171 and 191 and an increase in noncash stock-based compensation expense.
Net Loss $19.6 million for the 3 months ended September 30, 2025, compared to a net loss of $29.9 million for the same period in 2024. This was primarily due to an increase in revenue, partially offset by a decrease in interest income and an increase in income tax expense.
Cash, Cash Equivalents, and Marketable Securities $299.4 million as of September 30, 2025, which is a decrease compared to $324.2 million as of December 31, 2024. The decrease in cash resources did not include the $25 million milestone from J&J recognized in the third quarter and expected to be received in the fourth quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ZW191 Phase I trial: Initial clinical data presented at the ENA conference in October showed early clinical validation of the ADC approach. The drug demonstrated a favorable safety profile and promising antitumor activity, with objective responses observed at doses as low as 3.2 mg/kg. Two doses (6.4 mg/kg and 9.6 mg/kg) were selected for optimization.
ZW251 Phase I trial: First patient dosed in a Phase I clinical trial targeting GPC3 in hepatocellular carcinoma. The study aims to enroll approximately 100 participants and will evaluate safety, maximum tolerated dose, and efficacy.
ZW1528 preclinical data: Presented at the European Respiratory Society Annual Congress, targeting respiratory inflammation with a bispecific inhibitor of IL-4 and IL-31.
Partnership with J&J: Recognized a $25 million development milestone for clinical progress of pasritamig in Phase III studies. Eligible for up to $434 million in future milestones and mid-single-digit royalties on global product sales.
Partnership with Jazz: Earned $1 million in royalties from Ziihera net product sales. Jazz presented data on zanidatamab showing durable responses and a favorable safety profile.
Financial performance: Total revenue increased to $27.6 million in Q3 2025 from $16 million in Q3 2024, driven by a $25 million milestone from J&J and $1 million in royalties. Operating expenses decreased by 1% year-over-year, and net loss reduced to $19.6 million from $29.9 million.
Share repurchase program: Completed $22.7 million of the $30 million authorized share repurchase program, funded by development milestones and royalties.
Portfolio management: Discontinued development of ZW171 due to unmet internal thresholds, reallocating resources to higher-priority programs.
Leadership changes: Appointed Dr. Adam Schayowitz as acting Chief Development Officer and welcomed new directors to align governance with strategic goals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Development Risks: The company faces risks associated with regulatory approvals and clinical trial progress. Discontinuation of ZW171 highlights challenges in meeting internal thresholds for advancing therapies, which could impact the pipeline's success.
Financial Sustainability: Despite a decrease in net loss, the company experienced a reduction in cash resources from $324.2 million to $299.4 million. This could pose challenges in sustaining operations and funding future initiatives if anticipated milestones are not met.
Pipeline and Strategic Execution Risks: The decision to discontinue ZW171 reflects potential risks in pipeline prioritization and execution. Additionally, the reliance on partnerships for funding and development introduces dependency risks.
Market and Competitive Pressures: The company operates in a highly competitive oncology market, which could impact the adoption and success of its therapies. The need to demonstrate clear differentiation and efficacy is critical.
Supply Chain and Operational Risks: The company’s ability to efficiently manage clinical trials and supply chain logistics for its ADCs and other therapies is crucial. Any disruptions could delay progress and impact financials.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ZW191 Phase I Clinical Development: Enrollment for two dose optimization cohorts (6.4 mg/kg and 9.6 mg/kg) is expected to begin this quarter, with approximately 30 patients planned in each cohort. Additional data will be shared at a future medical conference.
ZW251 Phase I Clinical Development: The study is actively recruiting and aims to enroll approximately 100 participants across North America, Europe, and the Asia Pacific region. Part 1 will evaluate escalating doses to determine safety and maximum tolerated dose, while Part 2 will include randomized dose optimization at two selected doses.
Cash Resources and Funding Outlook: Existing cash resources, combined with anticipated regulatory milestones, are expected to fund planned operations into the second half of 2027, covering multiple catalyst events in the pipeline.
Partnership Revenue and Milestones: The company remains eligible to receive up to $434 million in development and commercial milestones from the J&J collaboration, in addition to potential mid-single-digit royalties on global product sales.
Strategic Partnerships and R&D Innovation: The company plans to continue leveraging partnerships to bring in external capital, accelerate development, and maintain control of R&D innovation while derisking clinical development.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: As of November 4, 2025, the company completed share repurchases of $22.7 million out of the remaining $30 million under the previously authorized share repurchase program. This program was primarily funded from development milestones and cumulative royalties received from Jazz and BeOne related to initial regulatory approvals in biliary tract cancer in the U.S. and China. The program reflects the leadership team's confidence in the company's outlook, the strength of its pipeline, and its long-term commitment to shareholder value. The action aligns with a disciplined, balanced approach to capital allocation designed to drive sustainable long-term returns.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you hear me?
A:Yes, we can hear you.
Q:What are your thoughts on the update in the PFS analysis for HERIZON-GEA to include the ITT rather than the PITT population?
A:We don't have anything to add beyond what Jazz has shared other than that we're aligned with the regulatory strategy they laid out for the readout of HERZON-01 and how to analyze that data.
Q:What does the folate receptor alpha data at Triple meeting mean for GPC3, especially in the liver cancer population?
A:The data is intriguing, and we are looking forward to continued recruitment of ZW191 in dose escalation and dose optimization. Hepatocellular carcinoma has high unmet medical need, and we believe our ADC construct can make a difference. The DAR4 construct was selected for safety, and preclinical studies show promising tolerability and efficacy.
Q:What are your thoughts on the payload irinotecan for liver cancer and the DLL3 CD3, CD28 trispecific IND?
A:Irinotecan is not a standard of care for liver cancer but has potential when delivered via ADC. The DLL3 trispecific design aims to address challenges with CD28 co-stimulation by ensuring simultaneous engagement of CD3 and CD28, which preclinical data supports.
Q:Would the increase to the intent-to-treat analysis increase the number of PFS events necessary to trigger the analysis?
A:Jazz provided all the guidance appropriate around that decision, and we don't want to go further than the guidance they've provided.
Q:How should we think about the starting dose levels of 251 relative to 191?
A:The schema for 251 is similar to 191, but with more confidence in the starting dose due to prior clinical experience. The starting dose has not been disclosed yet.
Q:How big is the universe of target antigens for a trispecific format beyond DLL3?
A:The technology can be applied to different targets in solid tumors and hematological cancers. The Azymetric platform allows for flexibility in designing molecules for selectivity and targeting.
Q:What gives you confidence that GPC3 will be active in the post-IL setting, and is there a need for a biomarker assay?
A:GPC3 expression is not modulated by IL treatment, and preclinical data supports its activity. A biomarker assay will be evaluated as data is collected.
Q:What are your expectations on durability for 191 and potential for combinations in earlier treatment lines?
A:The early responses and safety profile of 191 are encouraging, suggesting potential for durability and combination with other treatments in earlier lines of therapy.
Q:What are the learnings from 171 to 209, and how do they apply to the DLL3 program?
A:Learnings from 171, including QSP modeling and dose escalation strategies, are being applied to 209. The target toxicity profile and safety considerations for DLL3 are different but informed by prior experience.
Q:What is the correlation between H-score and PS2+ scoring methodologies?
A:H-score is a well-validated method that correlates well with PS2+ scoring. The high category in H-score aligns with high expression levels used for treatments like ELAHERE.
Q:How does ZW191 compare to competitors in low and intermediate folate receptor alpha expression patients?
A:ZW191 shows clinical activity across expression levels, including low and negative, and compares favorably to competitors in these populations.
Q:What differentiates ZW191 in terms of safety, especially for combinations in earlier treatment lines?
A:ZW191 has a favorable safety profile with lower rates of neutropenia, making it suitable for combinations in earlier treatment lines and prolonged treatment in maintenance settings.
Q:What are the key differentiators for the DLL3 trispecific molecule?
A:The DLL3 trispecific molecule aims to improve response rates and durability by incorporating CD28 co-stimulation, which preclinical data supports.
Q:What are the potential timelines for third-party milestones beyond Jazz?
A:Guidance on third-party milestones has not been provided, but updates may be shared as milestones become more probable.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the increase in PFS events due to the intent-to-treat analysis and provided limited guidance on third-party milestone timelines beyond Jazz.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC
BeOne
Clinical Development
Congress
ESMO
III study
PTK
Phase III
Phase ZW
President Clinical
RECIST
ZW insight
capital
carcinoma
castration prostate
development ZW
dos milligram
dose level
dose study
finding
generation cell
milestone JJ
milligram kilogram
mind
product profile
progress pasritamig
prostate cancer
recap
receptor alpha
reduction
safety dose
safety efficacy
share repurchase
size dose
study castration
treatment event
tumor size
ZYME Transcript
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Unknown5-9
The earnings call summary and Q&A reveal several concerning factors: a lack of forward guidance, delays in IND filing, and management's vague responses to critical questions. Additionally, pricing pressures and the need for partnerships indicate potential financial and operational challenges. These factors suggest a negative market sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Capstone Copper Corp. (CS:CA) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call highlights strong financial performance with increased revenue, net income, and EBITDA. Strategic initiatives in expanding copper production and targeting renewable energy markets are promising. The company anticipates revenue growth and improved margins, despite some regulatory and economic risks. Lack of shareholder return plans is a downside, but overall, the positive financial metrics and strategic outlook suggest a favorable stock price reaction.
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings report shows strong financial performance with 25% revenue growth and a shift to net income, indicating effective cost management. Positive cash flow and strategic initiatives in clinical development and partnerships further support a positive sentiment. Despite no updates on dividends or buybacks, the financial health and strategic outlook are favorable. No significant concerns were raised in the Q&A, reinforcing the positive sentiment.
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
ZYME Slides
ZYME Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
